#### Form 603

Corporations Act 2001 Section 671B

# Notice of initial substantial holder

To Company Name/ Scheme	CRESO PHARMA LIMITED
ACN/ ARSN	609 406 911
Details of substantial holder (1)  Name	L1 Capital Global Opportunites Master Fund
ACN/ ARSN (if applicable)	
The holder became a substantial holder on	23/06/2020

#### 2. Details of voting power

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in on the date the substantial holder became a substantial holder are as follows:

Class of securities (4)	Number of securities	Person's votes (5)	Voting power (6)
FPO	25,148,554	25,148,554	7.35%

<sup>\*</sup>Based on issued capital of 342,060,235 shares

## 3. Details of relevant interests

The nature of the relevant interest the substantial holder or an associate had in the following voting securities on the date the substantial holder became a substantial holder are as follows:

Holder of relevant interest	Nature of relevant interest (7)	Class and number of securities
See Schedule 1		

## 4. Details of present registered holders

The persons registered as holders of the securities referred to in paragraph 3 above are as follows:

Holder of relevant interest	Registered Holder of securities	Person entitled to be registered as holder (8)	Class and number of securities
See Schedule 1			

#### 5. Consideration

The consideration paid for each relevant interest referred to in paragraph 3 above, and acquired in the four months prior to the day that the substantial holder became a substantial holder is as follows:

Holder of relevant	Date of	Consideration (9)			
interest	interest	acquisition	Cash	Non-cash	Class and number of securities

			L	
			60	03 page 2/2 15 July 2001
Associates		4hb44'-  b- -	- <i>f</i> -ll	
e reasons the persons named in paragraph 3 above a	re associates of	the substantial holder are a	IS TOIIOWS:	
Name and ACN/ ARSN (if applicable)	Nature of ass	ociation		
N/A				

#### 7. Addresses

The addresses of persons named in this form are as follows:

Name	Address
	161a Shedden Road, One Artillery Court, Grand Cayman, Cayman
L1 Capital Global Opportunites Master Fund	Islands

Signature	•				
	Print name	David Feldman	Capacity	Director	
	Sign here	NHL	Date	26/06/2020	
			DIRECTIONS		
(1)	trust), the names could be	be included in an annexure to the form.	If the relevant interests of a group	ntion and its related corporations, or the n of persons are essentially similar, they n es of members is clearly set out in parag	nay be referred to throughout th
(2)	See the definition of "ass	ssociate" in section 9 of the Corporations	Act 2001.		
(3)	See the definition of "rele	levant interest" in sections 608 and 671E	B(7) of the Corporations Act 2001.		
(4)	The voting shares of a c	company constitute one class unless divi	ided into separate classes.		
(5)	The total number of vote	es attached to all the voting shares in the	e company or voting interests in th	e scheme (if any) that the person or an a	ssociate has a relevant
(6)	The person's votes divid	ded by the total votes in the body corpora	ate or scheme multiplied by 100.		
(7)	settin	ng out the terms of any relevant agreeme	ent, and a statement by the persor	was acquired. If subsection 671B(4) appli n giving full and accurate details of any cu lifying this contract, scheme or arrangem	ontract, scheme or

See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.

(8) If the substantial holder is unable to determine the identity of the person (eg. if the relevant interest arises because of an option) write "unknown".

any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).

(9)	Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.

# Schedule 1 - L1 Capital Global Opportunities Master Fund becoming a substantial holder in CRESO PHARMA LIMITED **Details of relevant interests**

Holder of relevant interest	Nature of relevant interest	Class and number of securities
L1 Capital Global Opportunities Master Fund	Power to (or to control) exercise vote and/or dispose of the securities as discretionary investment managers or advisers of superannuation funds, pooled superannuation trusts, managed investment schemes and investment management agreements.	Fully paid ordinary shares 25,148,554

# **Details of present registered holders**

Holder of relevant interest	Registered holder of securities	Persons entitled to be a registered holder	Class and number of securities
L1 Capital Global Opportunities Master Fund	Credit Suisse	Credit Suisse	25,148,554

25,148,554